Key result
LDL-apheresis gains wider acceptance for severe hypercholesterolemia through mechanisms beyond simple atherosclerotic plaque regression.
Why the study?
What is the current status and mechanism of clinical improvement of LDL-apheresis for the therapy of severe hyperlipidemia?
What is the current status and mechanism of clinical improvement of LDL-apheresis for the therapy of severe hyperlipidemia?
LDL-apheresis is gaining wider clinical acceptance for severe hypercholesterolemia, with mechanisms of benefit extending beyond plaque regression.
May inform decisions for refractory hypercholesterolemia; leaves open dominant mechanisms beyond plaque regression for prospective study.
The use of LDL-apheresis to treat patients with severe hypercholesterolemia has gained wider clinical acceptance during the past 2-3 years, particularly in patients with coronary artery disease. Systems utilizing immunoadsorption columns, dextran sulfate cellulose columns and heparin precipitation have been most commonly employed. New or improved technologies include whole-blood compatible columns, double-filtration plasmapheresis and lipoprotein (a)-apheresis. The mechanisms for clinical improvement extend beyond simple regression of atherosclerotic plaque.
No takes yet. Share an insight, caveat, or question.
Gordon et al. (1996) conducted a review in Severe hypercholesterolemia. LDL-apheresis was evaluated. LDL-apheresis has gained wider clinical acceptance for treating severe hypercholesterolemia, with mechanisms for clinical improvement extending beyond simple regression of atherosclerotic plaque.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: